Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Journal: The Lancet. Haematology
Published: May 23, 2025
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.
Journal: Targeted oncology
Published: April 03, 2025
DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.
Journal: International journal of hematology
Published: June 17, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2024
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.
Journal: Therapeutic advances in hematology
Published: April 11, 2024
Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Journal: International journal of hematology
Published: March 30, 2023
Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 17, 2022
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 22, 2022
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 05, 2021
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Journal: Future oncology (London, England)
Published: March 08, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Journal: International journal of cancer
Published: January 26, 2021
An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Journal: Journal of clinical pharmacology
Published: April 01, 2020
Last Updated: 09/26/2026